To shed further light on the eventual destiny of amyloid kidney deposits after interruption of amylogenic stimulus, we report a case of a 47-year-old woman with nephrotic syndrome due to renal amyloidosis, complicating abdominal Castleman’s disease. After 5 courses of therapy with melphalan and prednisolone which failed to improve the nephrotic syndrome or her general clinical condition, and 1 year after the diagnosis of renal amyloidosis, surgical excision of the abdominal mass was performed. Whereas her clinical symptoms and other laboratory findings rapidly improved, the proteinuria took 18 months to disappear. A second renal biopsy, performed 30 months after surgical resection, showed persistence of the amyloid deposits in the same extent. However, electron microscopy revealed subtle reparative phenomena at the epithelial site of the basement membrane. We conclude that proteinuria associated with amyloidosis does not only depend on structural damage and that the new synthesized segment of basement membrane observed by us probably represents a mechanism of repair and the start of a long healing process.

Keywords:
Amyloidosis, Castleman’s disease, Nephrotic syndrome
1.
Herrada J, Cabanillas F, Rice L, Manning J, Pugh W: The clinical behavior of localized and multicentric Castleman’s disease. Ann Intern Med 1998;128:657–662.
2.
Perfetti V, Bellotti V, Maggi A, Arbustini E, De Benedetti F, Paulli M, Marinone MG, Merlini G: Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman’s diease. Am J Hematol 1994;46:189–193.
3.
Ikeda S, Chisuwa H, Kawasaki S, Ozawa J, Hoshii Y, Yokota T, Aoi T: Systemic reactive amyloidosis associated with Castleman’s disease: Serial changes of the concentrations of acute phase serum amyloid A and interleukin-6 in serum. J Clin Pathol 1997;50:965–967.
4.
Lui SL, Chan KW, Li FK, Cheng IKP, Chan TM: Castleman’s disease and mesangial proliferative glomerulonephritis: The role of interleukin-6. Nephron 1998;78:323–327.
5.
Humphreys SR, Holley KE, Smith LH, McIlrath DC: Mesenteric angiofollicular lymph node hyperplasia (lymphoid hamartoma) with nephrotic syndrome. Mayo Clin Proc 1975;50:317–321.
6.
Ruggieri G, Barsotti P, Coppola G. Spinelli C, Balducci A, Ventola FR, D’Adamo G, Tata MV, Marinozzi V: Membranous nephropathy associated with giant lymph node hyperplasia. A case report with histological and ultrastructural studies. Am J Nephrol 1990;10:323–328.
7.
Weisenburger DD: Membranous nephropathy: Its association with multicentric angiofollicular lymph node hyperplasia. Arch Pathol Lab Med 1979;103:591–594.
8.
Said R, Tarawneh M: Membranoproliferative glomerulonephritis associated with multicentric angiofollicular lymph node hyperplasia. Am J Nephrol 1992;12:466–470.
9.
Chan TM, Cheng IKP, Wong KL, Chan KW: Resolution of membranoproliferative glomerulonephritis complicating angiofollicular lymph node hyperplasia (Castleman’s disease). Nephron 1993;65:628–632.
10.
Furuichi K, Wada T, Shimizu M, Segawa C, Ohta S, Takasawa K, Kobayashi K, Yokoyama H: Antimyeloperoxidase-antibody-positive rapidly progressive glomerulonephritis associated with Castleman’s disease. Nephrol Dial Transplant 1998;13:1556–1558.
11.
Tsukamoto Y, Hanada N, Nomura Y, Hiki Y, Kasai K, Shigematsu H, Kobayashi Y: Rapidly progressive renal failure associated with angiofollicular lymph node hyperplasia. Am J Nephrol 1991;11:430–436.
12.
Miadonna A, Salmaso C, Palazzi P, Elli E, Braidotti P, Lambertenghi-Deliliers G: Fibrillary glomerulonephritis in Castleman’s disease. Leuk Lymphoma 1998;28:429–435.
13.
Pilon VA, Gomez LG, Butler JJ: Systemic amyloidosis associated with a benign mesenteric lymphoid mass. Am J Clin Pathol 1982;78:112–116.
14.
Bonneau R, Paquin F, Giroux L: Angiofollicular lymph node hyperplasia of the plasma cell type with nephrotic syndrome and systemic amyloidosis: An unusual association. Lab Invest 1982;46:10A–11A.
15.
Chan WC, Hargreaves H, Keller J: Giant lymph node hyperplasia with unusual clinicopathologic features. Cancer 1984;53:2135–2139.
16.
West KP, Morgan DR, Lauder I: Angiofollicular lymph node hyperplasia with amyloidosis. Postgrad Med J 1989;65:108–111.
17.
Paydas S, Gonlusen G, Sagliker Y: Regression of nephrotic syndrome with colchicine therapy secondary to amyloidosis with associated Castleman’s disease. Nephron 1995;71:463–464.
18.
Montoli A, Minola E, Stabile F, Grillo C, Radaelli L, Spanti D, Luccarelli E, Spata C, Minetti L: End-stage renal failure from renal amyloidosis of the AA-type associated with giant lymph node hyperplasia (Castleman’s disease). Am J Nephrol 1995;15:142–146.
19.
Kazes I, Deray G, Jacobs C: Castleman’s disease and renal amyloidosis. Ann Intern Med 1995;122:395–396.
20.
Tanaka T, Horita M, Shibayama H, Seike M, Itoh Y, Hamaguchi K, Sato Y, Sakata T, Ishida T: Secondary amyloidosis associated with Castleman’s disease. Intern Med 1995;34:122–126.
21.
Arinsoy T, Yilmaz M, Ataoglu M, Bali M, Sindel S: Castleman’s disease with renal amyloidosis and nephrotic syndrome. Nephrol Dial Transplant 1997;12:2713–2716.
22.
Funabiki K, Kaneko S, Terajima M, Tomita H, Kawano Y, Tomino Y: A case of multicentric Castleman’s disease associated with renal amyloidosis and pure red cell aplasia. Am J Nephrol 1998;18:247–250.
23.
Keven K, Nergizoglu G, Ates K, Erekul S, Orhan D, Ertuk S, Tulunay O, Karetan O, Ergun Ertug A: Remission of nephrotic syndrome after removal of localized Castleman’s disease. Am J Kidney Dis 2000;35:1207–1211.
24.
Ordi J, Grau JM, Junqué A, Nomdedeu B, Palacin A, Cardesa A: Secondary (AA) amyloidosis associated with Castleman’s disease. Report of two cases and review of the literature. Am J Clin Pathol 1993;100:394–397.
25.
Garcia-San MJ, Rozman C, Palacin A, Nomdedeu B: Mesenteric hyaline plasma cell lymph node hyperplasia with amyloid deposits. Arch Intern Med 1981;141:261–263.
26.
Falk HM, Thonroth T, Skifvars B, Wegelius O: Resolution of renal amyloidosis secondary to rheumatoid arthritis. Acta Med Scand 1979;205:651–656.
27.
Van Gise H, Helmuchen U, Mikeler E, Bruning L, Walther C, Christ H, Mackensen S, Bohole A: Correlation between the morphological and clinical findings in a patient recovering from secondary generalized amyloidosis with renal involvement. Light and electron microscopic investigations on renal biopsies. Virchows Arch 1978;379:119–129.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.